Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Henry Khederian

Why Moderna Shares Are Trading Lower Following Novavax's Earnings Report

Moderna Inc (NASDAQ:MRNA) shares are trading lower by 3.15% at $131.52. Vaccine stocks are falling in sympathy with Novavax, Inc. (NASDAQ:NVAX), which reported worse-than-expected first-quarter EPS and sales results.

Novavax reported first-quarter revenue of $704 million, which came in below the $845.2 million estimate. The company reported quarterly earnings of $2.56 per share, which came in below the estimate of $2.69 per share... Read More

Moderna is a commercial-stage biotech. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine.

According to data from Benzinga Pro, Moderna has a 52-week high of $497.49 and a 52-week low of $122.01.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.